Researchers from Harvard Medical School and Spark Therapeutics Inc. tested subretinal NRF2 gene therapy in dry AMD models to investigate whether it could relieve oxidative stress and inflammation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results